ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 283 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.89 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $540 | -24.7% | 20,100 | 0.0% | 0.00% | -25.0% |
| Q2 2023 | $717 | +66.0% | 20,100 | +18.2% | 0.00% | +100.0% |
| Q1 2023 | $432 | -37.4% | 17,000 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $690 | -99.9% | 17,000 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $562,000 | -6.2% | 17,000 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $599,000 | -23.4% | 17,000 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $782,000 | -41.3% | 17,000 | -15.4% | 0.00% | -42.9% |
| Q4 2021 | $1,333,000 | +4.1% | 20,100 | -2.0% | 0.01% | 0.0% |
| Q3 2021 | $1,280,000 | -16.4% | 20,500 | +10.8% | 0.01% | -12.5% |
| Q2 2021 | $1,532,000 | +24.9% | 18,500 | 0.0% | 0.01% | +14.3% |
| Q1 2021 | $1,227,000 | -13.6% | 18,500 | 0.0% | 0.01% | -22.2% |
| Q4 2020 | $1,420,000 | +108.8% | 18,500 | +17.1% | 0.01% | +80.0% |
| Q3 2020 | $680,000 | -50.1% | 15,800 | -50.0% | 0.01% | -16.7% |
| Q2 2020 | $1,364,000 | -60.3% | 31,600 | -41.6% | 0.01% | -89.8% |
| Q4 2019 | $3,433,000 | – | 54,120 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Western Financial Corp/CA | 820,320 | $33,272,179 | 21.56% |
| Aquilo Capital Management, LLC | 1,103,515 | $44,758,568 | 16.81% |
| M28 Capital Management LP | 143,900 | $5,836,584 | 5.56% |
| WEALTH EFFECTS LLC | 155,620 | $6,311,951 | 3.60% |
| Evolutionary Tree Capital Management, LLC | 92,095 | $3,735,373 | 3.59% |
| Privium Fund Management B.V. | 221,015 | $8,867,122 | 3.36% |
| JOHNSON & JOHNSON | 247,598 | $10,043 | 2.92% |
| COMMODORE CAPITAL LP | 462,111 | $18,743 | 2.82% |
| Avidity Partners Management LP | 1,375,000 | $55,770,000 | 1.21% |
| Capital Impact Advisors, LLC | 26,853 | $1,089,158 | 1.06% |